This growth is driven by the growing demand for expertise.
According to Technavio forecasts, the global biologics contract development and manufacturing organization (CDMO) market size is expected to grow by US$10.63b from 2024 to 2028, with a growth rate of 10.46%.
This growth will be driven by the growing demand for expertise and advanced technologies in the production of complex biopharmaceutical products.
Niche CDMOs and biopharmaceutical CDMOs are leading the way in the production of biologics such as recombinant proteins and monoclonal antibodies.
Furthermore, the mammalian segment holds a significant market share owing to the increasing use of mammalian cells to produce therapeutic proteins for various diseases.
However, the market faces challenges in the production of small and large molecules, including biologics, monoclonal antibodies, and vaccines.
In addition, capacity utilization is also challenged due to the complex production process and the market playing an important role in the manufacturing of various therapeutics, especially biologics.
About 35% of CDMOs experience minor capacity utilization constraints in their manufacturing processes, while 20% experience moderate to severe constraints.
